Who Paid My Doc
Niv Ad
Takoma Park, MD Medical Doctor
NPI 1982673364 CMS profile 180834
7901 Maple Ave, Suite A, Takoma Park, MD 20912
General payments
$894,220
Research payments
$44,224
Ownership & investment interest
$49,371
Research they led as principal investigator
$165,872
Through program year 2025, Niv Ad of Takoma Park, MD is reported in the CMS Open Payments database as having received $894,220 across 302 general payments and $44,224 in research payments paid to them. Separately, studies naming them as principal investigator received $165,872 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $49,371 across 3 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $516,457 | 51 | |
| 2024 | General | $150,926 | 33 | |
| 2023 | General | $101,967 | 52 | |
| 2022 | General | $33,481 | 37 | |
| 2021 | General | $3,800 | 10 | |
| 2020 | General | $57,186 | 54 | |
| 2020 | Research | $2,688 | 2 | |
| 2019 | General | $30,403 | 65 | |
| 2019 | Research | $41,536 | 2 | |
| 2024 | Ownership | $16,457 | 1 | |
| 2023 | Ownership | $16,457 | 1 | |
| 2022 | Ownership | $16,457 | 1 |
Beside peers
- Niv Ad
- Maryland median
- Middle half of Maryland
- National median
In program year 2025, general payments to Niv Ad were reported at $516,457. Among 20,588 Maryland profiles paid that year, the median was $166 and the middle half received between $51 and $580.
Show as a table
| Year | Niv Ad | Maryland median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $30,403 | $165 | $50–$633 | $163 |
| 2020 | $57,186 | $114 | $37–$407 | $114 |
| 2021 | $3,800 | $130 | $36–$480 | $132 |
| 2022 | $33,481 | $150 | $45–$529 | $149 |
| 2023 | $101,967 | $155 | $47–$557 | $160 |
| 2024 | $150,926 | $169 | $53–$600 | $164 |
| 2025 | $516,457 | $166 | $51–$580 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
306 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.